Can pemetinib/dalbertam be taken without discontinuation for a long time?

The use of pemigatinib in cholangiocarcinoma (CCA) and some FGFR-positive hematological tumors reflects the long-term and individualized nature of disease management. For patients with advanced or metastatic cholangiocarcinoma, the recommended dose of pemetinib is typically 13.5 mg orally once daily for 14 days, followed by a 7-day pause in a 21-day cycle. This intermittent dosing strategy aims to balance drug efficacy and safety, reduce cumulative toxicity through periodic drug holidays, and allow patients to tolerate long-term treatment.

For patients with myeloid or lymphoid system tumors carryingFGFR1 rearrangements, pemetinib is administered continuously once daily until disease progression or intolerable toxicity occurs. This strategy embodies the concept of long-term management of targeted therapy. Compared with traditional chemotherapy, pemetinib's targeting mechanism allows it to continuously inhibit tumor cell proliferation over a longer period of time while maintaining quality of life. The feasibility of long-term use relies heavily on regular monitoring of blood parameters, liver and kidney function, and timely management of adverse reactions, such as hyperphosphatemia, abnormal liver function, and mild gastrointestinal reactions.

From a clinical practice perspective, the long-term administration strategy of pemetinib can not only delay disease progression, but also provide stable progression-free survival time. For patients and doctors, continued medication needs to strike a balance between efficacy and tolerability, and ensure continued effectiveness of treatment through periodic follow-up, imaging evaluation, and biochemical indicator monitoring. In other words, pemetinib can be used long-term, but the decision to discontinue the drug depends entirely on the patient's individual response, toxicity management, and treatment goals.

In general, the medication mode of pemetinib fully embodies the concept of precision medicine: through the identification of genetic characteristics, individualized treatment plans are formulated, while taking into account efficacy and safety in long-term management, providing sustainable targeted treatment options for patients with FGFR-positive tumors.

Reference materials:https://go.drugbank.com/drugs/DB15102